CD8A and ductal breast carcinoma in situ: In addition, the ratio of FOXP3+/CD8+ and FOXP3+/CD4+ cells in Milim Kim’s study [18], and CD8HLADR+/− and CD115+ cells in Michael J. Campbell’s study [32], were associated with recurrence-free survival in DCIS.